A $9B valuation for Neuralink prices in a future where brain implants are routine — but today's devices help a few dozen people in trials. Our read on the gap between capital and clinical reality. (Our opinion, not investment advice.)
Our read — labelled opinion, not investment advice.
Demos and valuations are easy to inflate; people living with an implant are not. The count of humans implanted is the hardest signal that a BCI has crossed from lab to clinic — and Synchron, not the loudest name, leads it.
BCIs trade off signal quality against surgical risk. Penetrating arrays (Neuralink) read the most; surface arrays (Precision) sit on the brain; vascular devices (Synchron) avoid open-brain surgery entirely. The tracker compares all three.
CU Anschutz · Caltech · USC — Surgeons at CU Anschutz/UCHealth implanted a BCI into a paralyzed patient's higher-functioning cortex — not the usual motor cortex — a world first, aiming for more natural and complete sensory-and-motor control. Part of a Caltech/USC consortium using a Blackrock Neurotech array.
Science Corporation — Science closed an oversubscribed $230M Series C (total ~$490M) to commercialize PRIMA — a retinal BCI that restored form vision in dry-AMD patients (NEJM-published). A European launch later this year would make it the first BCI vision product on the market.
Neuracle / NMPA (China) — China's NMPA cleared Neuracle's coin-sized NEO implant (developed with Tsinghua) for commercial sale to restore hand function after spinal-cord injury — the first invasive-class BCI approved for market anywhere, ahead of Neuralink.
UC Davis / BrainGate2 — A BrainGate2 intracortical BCI at UC Davis decoded a man with ALS's attempted speech into on-screen words and synthesized voice in real time at up to ~97-99% accuracy from a large vocabulary (NEJM) — the first speech BCI accurate enough for natural conversation. It has since been used independently at home for thousands of hours, marking the shift from lab demo to daily communication.